Loading page…

Report overview

The report highlights ROVI's international expansion, including the establishment of operations in Germany and the launch of its enoxaparin biosimilar there. It reports total revenue of 277.4 million euros and R&D&I investment of 28.3 million euros in 2017. Environmental figures show a 10% reduction in greenhouse gas emissions, alongside lower electricity and natural gas consumption.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2017
Period: 1 January 2017 – 31 December 2017
Language
Pages
File size

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Water consumption
Waste
Employees
Women on the board
Women in management

Materiality

Assessment
Basis
Matrix

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services